Dr. Chang, Yi-Cheng 's orcid link picture Dr. Chang, Yi-Cheng 's publons link picture Dr. Chang, Yi-Cheng 's Personal Homepage

Dr. Chang, Yi-Cheng

Joint Appointment Assistant Research Fellow
  • 02-23123456 ext 88656 (NTU) (Lab) (Room No: 343)
  • 02-33936523 (Fax)

Specialty:
  • Diabetes and Obesity
  • Genetic epidemiology

Education and Positions:
  • Education:

    M.D. -National Taiwan University

    Ph.D. -Academia Sinica and National Taiwan University Joint Ph.D. Program of Translational Medicine

     

    Position:

    - Associate Professor, Graduate Institute of Medical Genomics and Proteomics, Medical College, National Taiwan University

     

    - Attending Physician, Department of Endocrinology and Metabolism, National Taiwan University Hospital

     

    - Vice CEO, Center for Bariatric and Metabolic Surgery, National Taiwan University Hospital


Highlight Detail
...

Identification of Novel Biomarkers for Pre-diabetic Diagnosis Using a Combinational Approach

Dr. Chang, Yi-Cheng
Frontiers in Endocrinology , Apr 28, 2021

Reliable protein markers for pre-diabetes in humans are not clinically available. In order to identify novel and reliable protein markers for pre-diabetes in humans, healthy volunteers and patients diagnosed with pre-diabetes and stroke were recruited for blood collection. Blood samples were collected from healthy and pre-diabetic subjects 12 h after fasting. BMI was calculated from body weight and height. Fasting blood glucose (FBG), glycated hemoglobin (HbA1C), triglyceride (TG), total cholesterol, high-density lipoprotein, low-density lipoprotein (LDL), insulin and albumin were assayed by automated clinical laboratory methods. We used a quantitative proteomics approach to identify 1074 proteins from the sera of pre-diabetic and healthy subjects. Among them, 500 proteins were then selected using Mascot analysis scores. Further, 70 out of 500 proteins were selected via volcano plot analysis according to their statistical significance and average relative protein ratio. Eventually, 7 serum proteins were singled out as candidate markers for pre-diabetes due to their diabetic relevance and statistical significance. Immunoblotting data demonstrated that laminin subunit alpha 2 (LAMA2), mixed-lineage leukemia 4 (MLL4), and plexin domain containing 2 (PLXDC2) were expressed in pre-diabetic patients but not healthy volunteers. Receiver operating characteristic curve analysis indicated that the combination of the three proteins has greater diagnostic efficacy than any individual protein. Thus, LAMA2, MLL4 and PLXDC2 are novel and reliable serum protein markers for pre-diabetic diagnosis in humans.